Skip to main content
$36.37 -$1.05 (-2.8%)

04:00 PM EDT on 07/27/21

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.

Current Price $36.37 Mkt Cap $5.3B
Open $37.44 P/E Ratio 0.00
Prev. Close $36.37 Div. (Yield) $0.00 (0.0%)
Daily Range $35.76 - $37.92 Volume 962,845
52-Wk Range $34.43 - $64.37 Avg. Daily Vol. 1,366,434

Caps

How do you think NASDAQ:IONS will perform against the market?

Add Stock to CAPS Watchlist

All Players

791 Outperform
36 Underperform
 

All-Star Players

135 Outperform
7 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:IONS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

oncqueen (54.46)
Submitted February 20, 2015

They have a new anticoagulant which in 300 humans, given preoperatively for knee replacement, yielded NO clots (as opposed to 15% for Lovenox) and a bleeding risk of 5%, compared to 8% for Lovenox. This is a game-changer.

rofgile (99.61)
Submitted December 10, 2010

RNAi, please die.

NASDAQ:IONS VS S&P 500 (SPY)

Fools bullish on NASDAQ:IONS are also bullish on:

Fools bearish on NASDAQ:IONS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about IONS.

Recs

0
Member Avatar TMFAdriaCimino (26.96) Submitted: 7/3/2021 6:07:34 PM : Outperform Start Price: $40.22 NASDAQ:IONS Score: -10.78

Ionis has several candidates in the pipeline and expects to have at least 12 commercialized products by 2026. If that happens, we can expect a big increase in revenue over the coming years.

Recs

0
Member Avatar MKWas (< 20) Submitted: 2/18/2021 3:01:53 PM : Outperform Start Price: $57.84 NASDAQ:IONS Score: -49.36

A leaders in antisense oligonucleotides, an emerging technology used to control messenger RNA .

Recs

0
Member Avatar IndyAnthony (77.08) Submitted: 2/5/2021 11:57:00 PM : Underperform Start Price: $60.59 NASDAQ:IONS Score: +52.75

This biotech pharma company has out performed the S&P 500 over the last 10 years by hundreds of percent, but over the last 5 years, IONS has lost to the market by almost 30%, with most of those losses coming in 2020. The Founders are still involved, but institutions own almost 87% of the company. Despite collaborations with Roche, Biogen, and AstraZeneca, I think this company will underperform the market over the next 5-10 years.

Leaderboard

Find the members with the highest scoring picks in IONS.

Score Leader

yosemitebean

yosemitebean (37.13) Score: +612.44

The Score Leader is the player with the highest score across all their picks in IONS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
uclajphil6 < 20 1/7/2009 Underperform 3W $13.98 +160.16% +392.06% +231.91 0 Comment
JerryDreamer < 20 8/17/2009 Underperform 3W $15.37 +136.63% +346.25% +209.62 1 Comment
RXDOC73 97.97 11/22/2011 11/17/2020 Outperform NS $6.59 +451.90% +267.68% +184.22 1 Comment
Myshkin69 < 20 11/14/2011 Outperform 5Y $6.99 +420.31% +249.86% +170.45 0 Comment
loangolfer < 20 12/22/2011 11/14/2019 Outperform NS $6.99 +420.31% +250.59% +169.72 0 Comment
Santa22 < 20 9/22/2006 Outperform 3Y $7.02 +418.09% +255.02% +163.07 0 Comment
asterionc2 74.18 9/27/2006 Outperform 5Y $7.10 +412.25% +249.27% +162.98 0 Comment
jdmckeehan < 20 10/2/2006 Outperform 3Y $7.18 +406.55% +249.01% +157.54 0 Comment
John8464 < 20 9/15/2006 Outperform 1Y $7.23 +403.04% +251.04% +152.00 0 Comment
leadtip < 20 8/25/2006 Outperform 1Y $7.09 +412.98% +261.19% +151.79 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for IONS.